Primary Site >> Pancreatic Cancer
Gene >> MSLN
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. PMID: 8288629 |
Ref: Molecular cloning and expression of megakaryocyte potentiating factor cDNA. PMID: 7665620 |
Ref: Characterization, molecular cloning and expression of megakaryocyte potentiating factor. PMID: 11012204 |
Ref: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). PMID: 11751476 |
Ref: Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. PMID: 14695172 |
Ref: Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. PMID: 15017593 Ref: Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. PMID: 15140265 Ref: (111)In-Labeled CHX-A''-DTPA-conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin PMID: 22319803 |
Ref: Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. PMID: 15841046 Ref: Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. PMID: 16144939 |
Ref: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. PMID: 16467095 Ref: Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. PMID: 16647225 |
Ref: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. PMID: 17785569 Ref: High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. PMID: 17909009 |
Ref: Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. PMID: 18281514 Ref: Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. PMID: 19010822 Ref: Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. PMID: 19020717 Ref: Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. PMID: 19039293 Ref: Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma. PMID: 19081530 Ref: Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. PMID: 20357913 |
Ref: An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. PMID: 19818733 Ref: Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. PMID: 19843662 |
Ref: Suppression of cell death by the secretory form of N-terminal ERC/mesothelin. PMID: 20596597 |
Ref: A novel high-affinity human monoclonal antibody to mesothelin. PMID: 20635390 Ref: Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers. PMID: 21288909 Ref: Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. PMID: 21397388 Ref: Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. PMID: 21515913 Ref: Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. PMID: 21880146 |
Ref: Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. PMID: 22149739 Ref: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. PMID: 22320398 Ref: Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. PMID: 22487470 Ref: A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PMID: 22792233 Ref: A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer. PMID: 23028227 |
Ref: The role of mesothelin in tumor progression and targeted therapy. PMID: 22721387 Ref: Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer. PMID: 23233329 Ref: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. PMID: 23694968 Ref: Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells. PMID: 23874581 Ref: A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. PMID: 23989979 Ref: Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas. PMID: 24344503 |
Ref: Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. PMID: 24308545 Ref: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PMID: 24465798 Ref: Interleukin-6: a villain in the drama of pancreatic cancer development and progression. PMID: 25100121 Ref: An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. PMID: 25249555 Ref: Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis. PMID: 25550908 |
Ref: MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. PMID: 25336517 Ref: Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. PMID: 25756664 Ref: Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line. PMID: 25803818 Ref: A novel PET imaging using (6)(4)Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells. PMID: 25883990 Ref: Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with (8)(9)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. PMID: 26536664 |
Ref: T Cells Target Pancreatic Tumors. PMID: 26626535 Ref: Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis. PMID: 26874572 Ref: Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer. PMID: 26931187 Ref: Clinical impacts of mesothelin expression in gastrointestinal carcinomas. PMID: 27190694 Ref: Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. PMID: 27591765 Ref: Mesothelin Immunotherapy for Cancer: Ready for Prime Time? PMID: 27863199 |
Ref: Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. PMID: 27999204 Ref: Amatuximab and novel agents targeting mesothelin for solid tumors. PMID: 29184420 |
Ref: Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. PMID: 29157747 Ref: Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer. PMID: 29474384 Ref: Measurement of indicator genes using global complementary DNA (cDNA) amplification, by polyadenylic acid reverse transcriptase polymerase chain reaction (poly A RT-PCR): A feasibility study using paired samples from tissue and ductal juice in patients und PMID: 29574096 Ref: Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding. PMID: 29738555 Ref: Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses. PMID: 29854291 Ref: Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer. PMID: 29859625 Ref: Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. PMID: 30103775 Ref: Mesothelin as a target for cervical cancer therapy. PMID: 30324544 Ref: The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. PMID: 30333914 |